Akoya Biosciences Inc. recently announced an update regarding its merger activities. On April 28, 2025, the company entered into an Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and its subsidiary, Wellfleet Merger Sub, Inc. Under this agreement, Wellfleet Merger Sub will merge with and into Akoya, making Akoya a wholly owned subsidiary of Quanterix. Additionally, on May 20, 2025, Akoya disclosed it had received an unsolicited acquisition proposal from a third party, offering an all-cash transaction where each share of Akoya common stock would be exchanged for $1.40. Akoya's board is currently reviewing this proposal to determine if it could lead to a superior offer compared to the current merger agreement with Quanterix.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。